List 20 or more oncology drugs approved in or after 2020. Show in a markdown table only:…
- User
List 20 or more oncology drugs approved in or after 2020. Show in a markdown table only: Order no., Drug name(s), company, indication, year of approval. Sort table by drugname.
Assistant
Order No. Drug Name(s) Company Indication Year of Approval 1 Tivdak (fadolapdotin) Seerave Pharmaceuticals/Eisai Endometrial cancer 2021 2 Enhertu (trastuzumab deruxtecan) Daiichi Sankyo, AstraZeneca HER2-positive metastatic breast cancer, gastric or gastroesophageal junction adenocarcinoma 2020 3 Tepmetko (tepotinib) Merck KGaA, Pfizer Metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations 2021 4 Lurbinectedin PharmaMar Small cell lung cancer (SCLC) 2020 5 Libtayo (cemiplimab) Regeneron Pharmaceuticals, Sanofi Advanced cutaneous squamous cell carcinoma (CSCC) 2021 6 Peptide receptor radionuclide therapy (LuPSMA) Novartis Prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer 2022 7 Sotorasib (Amgen) Amgen KRAS G12C-mutated non-small cell lung cancer (NSCLC) 2021 8 Selinexor (Xpovio) Karyopharm Therapeutics Diffuse large B-cell lymphoma (DLBCL) 2020 9 Pirtobrutinib (M2698) Mundipharma/Eisai Mantle cell lymphoma (MCL) 2022 10 Obinutuzumab (Gazyva) Roche/Genentech Combination with venetoclax for chronic lymphocytic leukemia (CLL) 2020 11 Melflufen (Pepaxto) Oncopeptides Relapsed refractory multiple myeloma 2021 12 Margetuximab MacroGenics Metastatic HER2-positive breast cancer 2020 13 Masitinib (Kinavet) AB Science Systemic mastocytosis 2021 14 Leclazaomab Apobiologix Chronic lymphocytic leukemia (CLL) 2022 15 Dostarlimab (Jemperli) GlaxoSmithKline (GSK) dMMR endometrial cancer, mismatch repair deficient solid tumors 2021 16 Cibisatamab (M18-1763) MacroGenics B-cell malignancies 2022 17 Briumvi (birodotinib) F. Hoffmann-La Roche Eczema vaccinatum or eczema herpeticum 2021 18 Bimekizumab UCB Moderate-to-severe plaque psoriasis 2021 19 Belantamab mafodotin (Blenrep) GlaxoSmithKline (GSK) Relapsed or refractory multiple myeloma 2020 20 Balversa (erdafitinib) Janssen Pharmaceuticals Urothelial carcinoma with suspected FGFR alterations 2020 Please note that while I strive to provide accurate and up-to-date information, it is always a good idea to check with official sources for the most recent approvals and indications.
Other models, same or similar prompt
Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.